Author: Brenda Marie Rivers|| Date Published: March 3, 2021
The Biden administration is supporting collaboration between Johnson & Johnson (NYSE: JNJ) and Merck (NYSE: MRK) to produce more COVID-19 vaccine doses through the Defense Production Act.
At the White House’s request, the Department of Health and Human Services has earmarked $105 million in initial funds to help Merck (NYSE: MRK) expand company facilities in order to manufacture vaccine J&J developed to treat the novel coronavirus, HHS said Tuesday.
The DPA investment covers the production of vaccine substance and fill-finish vial procedures under the management of J&J’s Janssen Pharmaceuticals business.
HHS noted the large-scale vaccine manufacturing effort seeks to address the U.S. government’s goal of having 100 million vaccine doses available by the end of June.
Merck will update facilities to support vaccine validation and qualification activities with funds to be executed through the HHS’ Biomedical Advanced Research and Development Authority.
The White House also asked the Department of Defense to support J&J in daily logistics operations.
Brian Meyer, federal field chief technology officer at Axonius Federal, said cybersecurity asset management could help government agencies make dozens…
“Technology transformation company Red River has acquired Invictus International Consulting to expand its cybersecurity and enterprise modernization capabilities to support…
Synergy ECP, a software engineering, cybersecurity and systems engineering services provider, has acquired NetServices, a company offering secure, mission-focused technology services. The…
Precision Aerospace & Defense Group and FACT II Acquisition, a special purpose acquisition company, have signed a definitive business combination agreement to…
LMI has announced the acquisition of intellectual property and advanced capabilities to broaden its in-transit visibility and asset tracking services for…
